JP7724394B2 - イソインドリノン化合物 - Google Patents
イソインドリノン化合物Info
- Publication number
- JP7724394B2 JP7724394B2 JP2022521718A JP2022521718A JP7724394B2 JP 7724394 B2 JP7724394 B2 JP 7724394B2 JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022521718 A JP2022521718 A JP 2022521718A JP 7724394 B2 JP7724394 B2 JP 7724394B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered heterocycloalkyl
- branched
- compound
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01281/19 | 2019-10-09 | ||
| CH12812019 | 2019-10-09 | ||
| PCT/EP2020/078483 WO2021069705A1 (en) | 2019-10-09 | 2020-10-09 | Isoindolinone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551185A JP2022551185A (ja) | 2022-12-07 |
| JPWO2021069705A5 JPWO2021069705A5 (enExample) | 2023-10-17 |
| JP7724394B2 true JP7724394B2 (ja) | 2025-08-18 |
Family
ID=68242216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521718A Active JP7724394B2 (ja) | 2019-10-09 | 2020-10-09 | イソインドリノン化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220242846A1 (enExample) |
| EP (1) | EP4041231A1 (enExample) |
| JP (1) | JP7724394B2 (enExample) |
| WO (1) | WO2021069705A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021126973A1 (en) * | 2019-12-17 | 2021-06-24 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| JP2023545274A (ja) * | 2020-10-07 | 2023-10-27 | クルゲン（シャンハイ），インク． | 癌を処置する化合物および方法 |
| WO2022152822A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| EP4277901A1 (en) * | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| CN117242060A (zh) * | 2021-01-13 | 2023-12-15 | 蒙特罗萨医疗公司 | 异吲哚啉酮化合物 |
| US20240085421A1 (en) | 2021-01-13 | 2024-03-14 | Monte Rosa Therapeutics, Inc. | Methods for the identification of degrons |
| EP4313047A1 (en) * | 2021-03-22 | 2024-02-07 | Monte Rosa Therapeutics, Inc. | Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons |
| WO2022256623A1 (en) | 2021-06-04 | 2022-12-08 | Monte Rosa Therapeutics, Inc. | E3 ligase fusion proteins for proximity detection |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069720A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023091567A1 (en) | 2021-11-17 | 2023-05-25 | Monte Rosa Therapeutics, Inc. | Degron and neosubstrate identification |
| EP4508044A1 (en) | 2022-04-14 | 2025-02-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
| WO2024015855A1 (en) | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| CN119630648A (zh) * | 2022-07-14 | 2025-03-14 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮衍生物的制备方法及其晶形 |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| KR20250099113A (ko) | 2022-09-09 | 2025-07-01 | 이노보 테라퓨틱스 인코포레이티드 | CK1α 및 DUAL CK1α/GSPT1 분해 화합물 |
| WO2024201248A1 (en) * | 2023-03-24 | 2024-10-03 | Pin Therapeutics, Inc. | Compounds and methods for degrading gspt1 |
| WO2025051180A1 (zh) * | 2023-09-06 | 2025-03-13 | 上海超阳药业有限公司 | 内酰胺类衍生物及其应用 |
| WO2025085416A1 (en) * | 2023-10-16 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1 compounds and methods of use of the compounds |
| WO2025146112A1 (en) * | 2024-01-05 | 2025-07-10 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Gspt1 degrading compounds and compositions and uses thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525889A (ja) | 2000-12-27 | 2004-08-26 | セルジーン・コーポレーション | イソインドール−イミド化合物、組成物、およびそれらの使用 |
| JP2010502627A (ja) | 2006-08-30 | 2010-01-28 | セルジーン・コーポレーション | ５−置換イソインドリン化合物 |
| JP2012507541A (ja) | 2008-10-29 | 2012-03-29 | セルジーン コーポレイション | 癌の治療に使用するためのイソインドリン化合物 |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| JP2018517716A (ja) | 2016-05-05 | 2018-07-05 | エランコ ティーアゲズンタイト アーゲー | ヘテロアリール−１，２，４−トリアゾール及びヘテロアリール−テトラゾール化合物 |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230051120A (ko) * | 2020-03-31 | 2023-04-17 | 오름테라퓨틱 주식회사 | 신규분해약물 접합체 |
-
2020
- 2020-10-09 EP EP20789952.7A patent/EP4041231A1/en active Pending
- 2020-10-09 WO PCT/EP2020/078483 patent/WO2021069705A1/en not_active Ceased
- 2020-10-09 JP JP2022521718A patent/JP7724394B2/ja active Active
-
2022
- 2022-04-08 US US17/716,169 patent/US20220242846A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525889A (ja) | 2000-12-27 | 2004-08-26 | セルジーン・コーポレーション | イソインドール−イミド化合物、組成物、およびそれらの使用 |
| JP2010502627A (ja) | 2006-08-30 | 2010-01-28 | セルジーン・コーポレーション | ５−置換イソインドリン化合物 |
| JP2012507541A (ja) | 2008-10-29 | 2012-03-29 | セルジーン コーポレイション | 癌の治療に使用するためのイソインドリン化合物 |
| JP2018517716A (ja) | 2016-05-05 | 2018-07-05 | エランコ ティーアゲズンタイト アーゲー | ヘテロアリール−１，２，４−トリアゾール及びヘテロアリール−テトラゾール化合物 |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
Non-Patent Citations (3)
| Title |
|---|
| Annual Review of Pharmacology and Toxicology，2017年，Vol.57，p.107-123 |
| Drug Discovery Today: Technologies，2019年，Volume 31，Pages 29-34 |
| Nature，2016年，Vol.535(7611)，p.252-257 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021069705A1 (en) | 2021-04-15 |
| US20220242846A1 (en) | 2022-08-04 |
| EP4041231A1 (en) | 2022-08-17 |
| JP2022551185A (ja) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7724394B2 (ja) | イソインドリノン化合物 | |
| US11912682B2 (en) | Isoindolinone compounds | |
| EP3853234B1 (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| TWI844568B (zh) | 抑制shp2活性化合物之製造方法、及由酸加成產生之產物 | |
| JP7649289B2 (ja) | アルキニルキナゾリン化合物 | |
| US11034672B1 (en) | Tyrosine kinase inhibitor compositions, methods of making and methods of use | |
| RU2699546C2 (ru) | Комбинированная терапия для лечения рака | |
| KR102534028B1 (ko) | 트리아졸로피리미딘 화합물 및 그의 용도 | |
| US20240051936A1 (en) | Isoindolinone compounds | |
| US20240051937A1 (en) | Isoindolinone amide compounds useful to treat diseases associated with gspt1 | |
| WO2022015670A1 (en) | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors | |
| WO2022170052A1 (en) | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof | |
| CN117242060A (zh) | 异吲哚啉酮化合物 | |
| EA048940B1 (ru) | Соединения алкинилхиназолина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231006 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241003 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250402 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250416 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250508 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250613 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250613 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7724394 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |